Cascade BioSciences Inc.
TSX: CSBXMid-cap oncology developer. Lead candidate CSB-204 in Phase II. Disclosure quality has deteriorated across the last two reporting cycles.
Open flags
Revenue restated in the financials but not flagged in the narrative
Contradiction
The 2023 MD&A booked $4.0M of Merevix milestones as revenue in full. The 2024 financials quietly restate that and defer $2.1M of it — but the cover-page narrative never mentions a restatement.
74
score
Press release promises timelines without required disclaimers
Disclosure Integrity
The Phase II press release claims regulatory approval and commercial launch are on track, but doesn't include the standard risk factors and assumptions that are required for that kind of forward-looking statement.
44
score